 | This articleneeds additional citations forverification. Please helpimprove this article byadding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Eperisone" – news ·newspapers ·books ·scholar ·JSTOR(January 2024) (Learn how and when to remove this message) |
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Myonal |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H25NO |
| Molar mass | 259.393 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Eperisone (formulated as theeperisone hydrochloride salt) is anantispasmodic drug.
Eperisone acts by relaxing bothskeletal muscles andvascular smooth muscles, and demonstrates a variety of effects such as reduction ofmyotonia, improvement ofcirculation, and suppression of the pain reflex. The drug inhibits the vicious circle of myotonia by decreasing pain,ischaemia, andhypertonia in skeletal muscles, thus alleviating stiffness andspasticity, and facilitating muscle movement[1]
Eperisone also improvesdizziness andtinnitus associated withcerebrovascular disorders orcervical spondylosis.
Eperisone has a relatively low incidence ofsedation when compared with other antispasmodic drugs; this simplifies theclinical application of the drug and makes it an attractive choice for patients who require antispasmodic therapy without a reduction inalertness.
Eperisone also facilitates voluntary movement of the upper and lowerextremities without reducing muscle power; it is therefore useful during the initial stage ofrehabilitation and as a supporting drug during subsequent rehabilitativetherapy.
Eperisone hydrochloride is available as the brand name preparations Myonal and Epry as 50 mgsugar-coated tablets, or as 10% granules for oral administration.[6] An experimental form of the drug, as atransdermal patch system, has shown promising results in laboratory tests on rodents; however, this product is not currently available for human use.[7]
In adults, the usual dose of eperisone is 50–150 mg per day, in divided doses, after meals. However, the dosage is adjusted by theprescribingclinician depending on factors such as severity ofsymptoms, patient age and response.
Eperisone has not been established as definitely safe forpaediatric use, therefore its use in paediatrics cannot be recommended without further study.[6]
Ifelderly patients are treated with eperisone, a reduced dose is recommended, and the patient should be closely monitored for signs of physiological hypofunction during treatment.[6]
Eperisone has not been established to be safe for use bypregnant women; therefore the drug should not be used in pregnant women, or women who may be pregnant, if the expectedtherapeutic benefits will outweigh the possible risks associated with treatment. The manufacturers of Myonal recommend the drug not be used duringlactation (breast-feeding). If eperisone must be used, the patient is advised to stop breast-feeding for the duration of treatment. Eperisone has been reported to be excreted in breast milk in an animal study (in rats).
Eperisone iscontraindicated in patients with knownhypersensitivity to the drug.[8]Side effects: 'very rare' excessive relaxation, stomachache, nausea, vertigo, anorexia, drowsiness, skin rashes, diarrhoea, vomiting, indigestion, GI disturbances, insomnia, headache, constipation etc.[9]
Eperisone should be administered with care in patients with a history of hypersensitivity to any medication, or with disorders ofliver function (it may aggravate hepatic dysfunction).
Weakness,light-headedness,sleepiness or othersymptoms may occur. In the event of such symptoms, the dosage should be reduced or treatment discontinued. Patients should be cautioned against engaging in potentially hazardous activities requiring alertness, such as operating machinery or driving a car.[6]
There have been reports of disturbances inocularaccommodation occurring after the concomitant use of the related drugtolperisone hydrochloride andmethocarbamol.
Seizures have been reported in an infant after accidental ingestion of eperisone.[11]
Eperisone suffers from a very lowbioavailability when taken orally, as a result of highfirst pass intestinalmetabolism; atransdermal patch containing eperisone is currently in development inSouth Korea.[1] This has shown promise, with the antispasmodic effect lasting over 24 hours, compared to one to two hours following oral administration.
Eperisone is also under investigation as anantihypertensive agent, with promising results from trials onbeagles.[12]
Eperisone is marketed under many brand names worldwide.[13]
Chemically and mechanistically related drugs:
